We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Ultraviolet-A and Riboflavin Treatment for Infectious Keratitis

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01739673
First Posted: December 3, 2012
Last Update Posted: February 3, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Cxlusa
  Purpose
This study is to evaluate the efficacy of ultraviolet-A (UVA) and riboflavin application (also often referred to as corneal collagen crosslinking) as a method to enhance treatment of infectious keratitis.

Condition Intervention
Infectious Keratitis Other: Ultraviolet-A and riboflavin

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Ultraviolet-A and Riboflavin Treatment for Infectious Keratitis

Resource links provided by NLM:


Further study details as provided by Cxlusa:

Primary Outcome Measures:
  • Resolution of Signs and Symptoms of Infectious Keratitis [ Time Frame: Subjects will be followed until resolution of signs and symptoms, an expected average of 8 weeks ]

Estimated Enrollment: 1000
Study Start Date: August 2011
Study Completion Date: July 2014
Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Ultraviolet-A and riboflavin Other: Ultraviolet-A and riboflavin

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subjects must be 18 years of age or older.
  2. Ability to provide written informed consent.
  3. Likely to complete all study visits.
  4. Subjects must have one eye that with a diagnosis of infectious keratitis.

Exclusion Criteria:

  1. A corneal perforation.
  2. Descemetocele.
  3. Pregnancy or breastfeeding.
  4. Active Herpes corneal disease.
  5. Patient is unwilling or unable to comply with a medication regimen and follow up appointments.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01739673


Locations
United States, Arizona
Schwartz Laser Eye Center
Scottsdale, Arizona, United States
United States, California
Davidorf Eye Group
West Hills, California, United States
United States, Colorado
Corneal Consultants of Colorado, PC
Littleton, Colorado, United States
United States, Florida
Center for Excellence in Eye Care
Miami, Florida, United States
United States, Minnesota
Minnesota Eye Consultants
Minneapolis, Minnesota, United States
United States, Missouri
Ophthalmology Associates
St. Louis, Missouri, United States
Sponsors and Collaborators
Cxlusa
Investigators
Study Director: William Trattler, MD Center For Excellence In Eye Care
  More Information

Responsible Party: Cxlusa
ClinicalTrials.gov Identifier: NCT01739673     History of Changes
Other Study ID Numbers: iCXL
First Submitted: November 27, 2012
First Posted: December 3, 2012
Last Update Posted: February 3, 2017
Last Verified: August 2015

Keywords provided by Cxlusa:
Infectious Keratitis

Additional relevant MeSH terms:
Keratitis
Communicable Diseases
Infection
Corneal Diseases
Eye Diseases
Riboflavin
Vitamin B Complex
Vitamins
Micronutrients
Growth Substances
Physiological Effects of Drugs
Photosensitizing Agents
Dermatologic Agents